IN2015DN00143A - - Google Patents
Info
- Publication number
- IN2015DN00143A IN2015DN00143A IN143DEN2015A IN2015DN00143A IN 2015DN00143 A IN2015DN00143 A IN 2015DN00143A IN 143DEN2015 A IN143DEN2015 A IN 143DEN2015A IN 2015DN00143 A IN2015DN00143 A IN 2015DN00143A
- Authority
- IN
- India
- Prior art keywords
- antibodies
- family member
- disclosed
- cell death
- positive cells
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/35—Valency
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12305821.6A EP2684896A1 (en) | 2012-07-09 | 2012-07-09 | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
| US201261669866P | 2012-07-10 | 2012-07-10 | |
| PCT/EP2013/064466 WO2014009358A1 (en) | 2012-07-09 | 2013-07-09 | Anti-dr5 family antibodies, bispecific or multivalent anti-dr5 family antibodies and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IN2015DN00143A true IN2015DN00143A (enExample) | 2015-06-12 |
Family
ID=46514282
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IN143DEN2015 IN2015DN00143A (enExample) | 2012-07-09 | 2013-07-09 |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US9611327B2 (enExample) |
| EP (3) | EP2684896A1 (enExample) |
| JP (1) | JP6457386B2 (enExample) |
| CN (1) | CN104619725B (enExample) |
| BR (1) | BR112015000449B1 (enExample) |
| CA (1) | CA2878790C (enExample) |
| DK (1) | DK2877491T3 (enExample) |
| ES (1) | ES2727486T3 (enExample) |
| IL (2) | IL236651B (enExample) |
| IN (1) | IN2015DN00143A (enExample) |
| PL (1) | PL2877491T3 (enExample) |
| PT (1) | PT2877491T (enExample) |
| SG (2) | SG11201500177PA (enExample) |
| SI (1) | SI2877491T1 (enExample) |
| WO (1) | WO2014009358A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3247728T (pt) | 2015-01-20 | 2020-07-16 | Igm Biosciences Inc | Moléculas de ligação do recetor da superfamília do fator de necrose tumoral (fnt) e utilização das mesmas |
| EP3048116A1 (en) * | 2015-01-23 | 2016-07-27 | International-Drug-Development-Biotech | Anti-dr5 antibodies with enhanced apoptosis potency |
| CN107250161A (zh) * | 2015-01-26 | 2017-10-13 | 宏观基因有限公司 | 包含dr5‑结合结构域的多价分子 |
| EP3112381A1 (en) * | 2015-07-01 | 2017-01-04 | FONDAZIONE IRCCS Istituto Nazionale dei Tumori | Bispecific antibodies for use in cancer immunotherapy |
| JP6807606B2 (ja) | 2015-07-16 | 2021-01-06 | インヒブルクス インコーポレイテッド | 多価及び多重特異性ｄｒ５結合融合タンパク質 |
| MX2018006333A (es) | 2015-12-01 | 2018-08-01 | Genmab Bv | Anticuerpos anti-receptor de muerte 5 (dr5) y metodos de uso de los mismos. |
| CN106397594B (zh) * | 2016-10-25 | 2019-06-04 | 中国药科大学 | 一种全人源的抗人死亡受体5的激动剂单链抗体及应用 |
| EP3535291A1 (en) | 2016-11-01 | 2019-09-11 | Genmab B.V. | Polypeptide variants and uses thereof |
| EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
| BR112019015900A2 (pt) | 2017-02-10 | 2020-04-07 | Genmab B.V. | polipeptídeo, métodos para aumentar a atividade agonística de um polipeptídeo, para aumentar a atividade de cdc de um polipeptídeo e de tratamento de um indivíduo tendo uma doença, composição, kit de partes, e, uso de um polipeptídeo ou uma composição |
| KR101926834B1 (ko) * | 2017-03-21 | 2018-12-07 | 동아에스티 주식회사 | 항-dr5 항체 및 그의 용도 |
| EP3635005A1 (en) | 2017-06-07 | 2020-04-15 | Genmab B.V. | Therapeutic antibodies based on mutated igg hexamers |
| US12649798B2 (en) | 2018-01-24 | 2026-06-09 | Genmab B.V. | Polypeptide variants and uses thereof |
| EP3759229A4 (en) * | 2018-02-26 | 2021-12-29 | IGM Biosciences Inc. | Use of a multimeric anti-dr5 binding molecule in combination with a chemotherapeutic agent for treating cancer |
| MX2020011552A (es) | 2018-05-03 | 2020-11-24 | Genmab Bv | Combinaciones de variantes de anticuerpos y usos de las mismas. |
| US12247075B2 (en) * | 2018-12-26 | 2025-03-11 | Imcheck Therapeutics Sas | BTN3A binding proteins and uses thereof |
| US20220315661A1 (en) | 2019-05-09 | 2022-10-06 | Genmab B.V. | Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer |
| JP7880817B2 (ja) | 2019-11-06 | 2026-06-26 | ジェンマブ ビー．ブイ． | 抗体変種の組み合わせおよびその使用 |
| US20230293680A1 (en) | 2020-07-23 | 2023-09-21 | Genmab B.V. | A composition of anti-dr5 antibodies and an immunomodulatory imide drug for use in treating multiple myeloma |
| JP2025510548A (ja) * | 2022-03-02 | 2025-04-15 | ウォルデン バイオサイエンシズ，インコーポレイティド | 新規の可溶性ウロキナーゼ型プラスミノーゲン活性化因子受容体（ｓｕＰＡＲ）結合性分子及びその使用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4342566A (en) | 1980-02-22 | 1982-08-03 | Scripps Clinic & Research Foundation | Solid phase anti-C3 assay for detection of immune complexes |
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5204244A (en) | 1987-10-27 | 1993-04-20 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5202238A (en) | 1987-10-27 | 1993-04-13 | Oncogen | Production of chimeric antibodies by homologous recombination |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US6284236B1 (en) | 1995-06-29 | 2001-09-04 | Immunex Corporation | Cytokine that induces apoptosis |
| CA2249206A1 (en) | 1996-04-01 | 1997-10-09 | Genentech, Inc. | Apo-2li and apo-3 apoptosis polypeptides |
| ATE362982T1 (de) | 1997-01-28 | 2007-06-15 | Human Genome Sciences Inc | ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET |
| US6872568B1 (en) | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
| US20050233958A1 (en) | 1997-03-17 | 2005-10-20 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
| CA2318029C (en) * | 1998-01-15 | 2009-05-19 | Genentech, Inc. | Apo-2 ligand |
| EP1049787B1 (en) | 1998-01-23 | 2004-11-24 | Vlaams Interuniversitair Instituut voor Biotechnologie | Multipurpose antibody derivatives |
| CA2323757C (en) | 1998-04-02 | 2011-08-02 | Genentech, Inc. | Antibody variants and fragments thereof |
| ATE330972T1 (de) | 1999-06-09 | 2006-07-15 | Genentech Inc | Apo-2l rezeptor-agonist und cpt-11 synergie- effekt |
| US6444640B1 (en) | 1999-09-30 | 2002-09-03 | Ludwig Institute For Cancer Research | Compositions of trail and DNA damaging drugs and uses thereof |
| US7279160B2 (en) | 2000-05-02 | 2007-10-09 | The Uab Research Foundation | Combinations of DR5 antibodies and other therapeutic agents |
| GB0020442D0 (en) | 2000-08-18 | 2000-10-04 | Nokia Networks Oy | Data transmission protocol |
| US20020155109A1 (en) | 2001-04-20 | 2002-10-24 | Lynch David H. | Bispecific antibodies that bind TRAIL-R1 and TRAIL-R2 |
| MXPA03010747A (es) | 2001-05-25 | 2004-03-02 | Human Genome Sciences Inc | Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral. |
| JP4509570B2 (ja) | 2001-07-03 | 2010-07-21 | ジェネンテック， インコーポレイテッド | ヒトｄｒ４抗体及びその使用法 |
| KR20070010046A (ko) | 2004-04-06 | 2007-01-19 | 제넨테크, 인크. | Ｄｒ5 항체 및 그의 용도 |
| AU2005335714B2 (en) | 2004-11-10 | 2012-07-26 | Macrogenics, Inc. | Engineering Fc antibody regions to confer effector function |
| WO2006093794A1 (en) | 2005-02-28 | 2006-09-08 | Centocor, Inc. | Heterodimeric protein binding compositions |
| JP2009529331A (ja) | 2006-03-10 | 2009-08-20 | マクロジェニクス，インコーポレーテッド | 変異型重鎖を有する抗体の同定および工学的改変ならびにその使用方法 |
| KR100847010B1 (ko) * | 2006-07-05 | 2008-07-17 | 아주대학교산학협력단 | 세포사멸 수용체 5 (ｄｒ5)에 특이적으로 결합하는 항체 및이를 포함하는 암 예방 또는 치료용 조성물 |
| WO2009002947A2 (en) | 2007-06-22 | 2008-12-31 | Affymax, Inc. | Compounds and peptides that bind the trail receptor |
| UA117901C2 (uk) * | 2011-07-06 | 2018-10-25 | Ґенмаб Б.В. | Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування |
-
2012
- 2012-07-09 EP EP12305821.6A patent/EP2684896A1/en not_active Withdrawn
-
2013
- 2013-07-09 PL PL13734785T patent/PL2877491T3/pl unknown
- 2013-07-09 DK DK13734785.2T patent/DK2877491T3/da active
- 2013-07-09 CN CN201380036952.2A patent/CN104619725B/zh active Active
- 2013-07-09 US US14/413,194 patent/US9611327B2/en active Active
- 2013-07-09 WO PCT/EP2013/064466 patent/WO2014009358A1/en not_active Ceased
- 2013-07-09 SG SG11201500177PA patent/SG11201500177PA/en unknown
- 2013-07-09 SI SI201331443T patent/SI2877491T1/sl unknown
- 2013-07-09 EP EP13734785.2A patent/EP2877491B1/en active Active
- 2013-07-09 IN IN143DEN2015 patent/IN2015DN00143A/en unknown
- 2013-07-09 EP EP19159204.7A patent/EP3575323B1/en active Active
- 2013-07-09 SG SG10201700148UA patent/SG10201700148UA/en unknown
- 2013-07-09 BR BR112015000449-0A patent/BR112015000449B1/pt active IP Right Grant
- 2013-07-09 JP JP2015520954A patent/JP6457386B2/ja active Active
- 2013-07-09 PT PT13734785T patent/PT2877491T/pt unknown
- 2013-07-09 CA CA2878790A patent/CA2878790C/en active Active
- 2013-07-09 ES ES13734785T patent/ES2727486T3/es active Active
-
2015
- 2015-01-11 IL IL23665115A patent/IL236651B/en active IP Right Grant
-
2017
- 2017-02-17 US US15/436,583 patent/US10647774B2/en active Active
-
2019
- 2019-09-22 IL IL269527A patent/IL269527B/en unknown
-
2020
- 2020-04-06 US US16/841,306 patent/US20200332016A1/en not_active Abandoned
-
2023
- 2023-09-06 US US18/461,910 patent/US20240141057A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA2878790C (en) | 2023-09-26 |
| IL269527B (en) | 2021-12-01 |
| DK2877491T3 (da) | 2019-06-03 |
| US20200332016A1 (en) | 2020-10-22 |
| BR112015000449A2 (enExample) | 2017-08-15 |
| PL2877491T3 (pl) | 2020-01-31 |
| EP2877491A1 (en) | 2015-06-03 |
| SG10201700148UA (en) | 2017-02-27 |
| IL236651B (en) | 2019-10-31 |
| US9611327B2 (en) | 2017-04-04 |
| BR112015000449B1 (pt) | 2022-12-20 |
| ES2727486T3 (es) | 2019-10-16 |
| EP3575323B1 (en) | 2024-09-11 |
| PT2877491T (pt) | 2019-06-07 |
| IL236651A0 (en) | 2015-02-26 |
| US20240141057A1 (en) | 2024-05-02 |
| SI2877491T1 (sl) | 2019-08-30 |
| WO2014009358A1 (en) | 2014-01-16 |
| CN104619725A (zh) | 2015-05-13 |
| EP2684896A1 (en) | 2014-01-15 |
| HK1211044A1 (en) | 2016-05-13 |
| CN104619725B (zh) | 2019-04-23 |
| JP6457386B2 (ja) | 2019-01-23 |
| US10647774B2 (en) | 2020-05-12 |
| CA2878790A1 (en) | 2014-01-16 |
| US20170260281A1 (en) | 2017-09-14 |
| JP2015527992A (ja) | 2015-09-24 |
| SG11201500177PA (en) | 2015-03-30 |
| EP3575323A1 (en) | 2019-12-04 |
| US20150139997A1 (en) | 2015-05-21 |
| EP2877491B1 (en) | 2019-02-27 |
| IL269527A (en) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB2515195B (en) | Improved fuel cell systems and methods | |
| HUE052599T2 (hu) | CD4+ szabályozó T-sejtek fokozására szolgáló eljárások és készítmények | |
| EP3480321B8 (en) | Massively parallel single cell analysis | |
| IL244511A0 (en) | Cell culture in a metabolically optimal manner | |
| EP3082840A4 (en) | Methods and assays relating to circulating tumor cells | |
| EP2970881A4 (en) | Compositions and methods for reprogramming hematopoietic stem cell lineages | |
| IL240881A0 (en) | Expression of the t cell balance gene, preparations, materials and methods for its use | |
| EP3114716A4 (en) | Battery cells and arrangements | |
| EP3028328A4 (en) | Electro-synthetic or electro-energy cell with gas diffusion electrode(s) | |
| EP3083658A4 (en) | Methods and assays relating to circulating tumor cells | |
| EP3080855A4 (en) | Electrochemical cells and components thereof | |
| EP3147974A4 (en) | Battery assembly and cell pack | |
| EP3072953A4 (en) | Cell culture container and container in which cell culture has been accommodated | |
| EP3052104A4 (en) | Treating inflammation using llp2a-bisphosphonate conjugates and mesenchymal stem cells | |
| GB201319966D0 (en) | Fuel cell assembly and method | |
| EP3046171A4 (en) | Fuel cell and fuel cell stack | |
| GB201418271D0 (en) | Fuel cell and battery | |
| EP3087193A4 (en) | Compositions and methods for providing active telomerase to cells in vivo | |
| EP2919309A4 (en) | SEALING MEMBER FOR FUEL CELL AND SEALING BODY FOR FUEL CELL USING SAME | |
| GB201306326D0 (en) | Fuel cells | |
| ZA201505170B (en) | Tablets with improved acceptance and good storage stability | |
| GB201401981D0 (en) | Fuel cell and battery | |
| EP3164127A4 (en) | Compositions and methods to improve adoptive cell therapies | |
| KR101882068B1 (ko) | 연료 전지의 작동 | |
| EP2970883B8 (en) | Enhanced placental stem cells and uses thereof |